Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carilex MedicalROCO:7726 42 EV-to-EBITDA is 39.82 as of Sep. 13, 2026, which is 243% above its 10-year median of 11.62. GuruFocus rates ROCO:7726 with a GF Score™ of 42/100. The stock has 5 warning signs investors should review. Among 515 Medical Devices & Instruments companies, Carilex Medical ranks worse than 85.63% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Carilex Medical's enterprise value is NT$575.2 Mil.
Carilex Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$14.4 Mil. Therefore, Carilex Medical's EV-to-EBITDA for today is 39.82.
The historical rank and industry rank for Carilex Medical's EV-to-EBITDA or its related term are showing as below:
ROCO:7726'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -143.76 Med: 11.62 Max: 39.82
Current: 39.82
During the past 6 years, the highest EV-to-EBITDA of Carilex Medical was 39.82. The lowest was -143.76. And the median was 11.62.
ROCO:7726's EV-to-EBITDA is ranked worse than 85.63% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 13.63
vs ROCO:7726: 39.82
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Carilex Medical (ROCO:7726) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Carilex Medical's PE Ratio (TTM) for today is calculated as:
Carilex Medical's share price for today is NT$32.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Carilex Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-0.613.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Carilex Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7726 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Carilex Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carilex Medical EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carilex Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Carilex Medical's EV-to-EBITDA falls into.
Carilex Medical's current Enterprise Value is NT$575.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Carilex Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$14.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carilex Medical (ROCO:7726) has a EV-to-EBITDA of 39.82 as of Sep. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Carilex Medical. This is 243% above median its historical median of 11.62. According to the industry distribution chart, Carilex Medical ranks #441 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 85.6%.
Is Carilex Medical's EV-to-EBITDA too high?
Carilex Medical's current EV-to-EBITDA of 39.82 is 243% above median its 10-year median of 11.62. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.63. Carilex Medical's value of 39.82 is 192.1% above this industry median. Based on the distribution chart, Carilex Medical ranks #441 out of 515 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Carilex Medical has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Carilex Medical's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Carilex Medical ranks #441 out of 515 companies for EV-to-EBITDA. This places Carilex Medical in the lower half of its industry. The industry median EV-to-EBITDA is 13.63. Carilex Medical's value of 39.82 is 192.1% above this benchmark. While the company's 10-year median is 11.62 vs. the industry median of 13.63, Carilex Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.63, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carilex Medical's current EV-to-EBITDA of 39.82 is 192.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Carilex Medical. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carilex Medical's current EV-to-EBITDA is 39.82, which is 243% above median its own 10-year median of 11.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carilex Medical stock overvalued right now?
Carilex Medical (ROCO:7726) has a current EV-to-EBITDA of 39.82. The current EV-to-EBITDA is 39.82, which is 243% above median its 10-year median of 11.62 and 192.1% above the Medical Devices & Instruments industry median of 13.63. Carilex Medical's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Carilex Medical (ROCO:7726), the current EV-to-EBITDA is 39.82 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.
42GF Score
Get the complete analysis for ROCO:7726
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7726 has been successfully added to your 
